A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2015
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 22 May 2014 As per NCT official title get changed from 2 cohort to 3 cohort and hence number of treatment arms changed from 2 to 3.
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Apr 2013 Planned End Date changed from 1 Dec 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.